Testosterone cypionate for TRT: what the evidence actually shows

What did @kmartfit actually say?

The creator says they personally take "testosterone-ciphyenate" (testosterone cypionate) at 180 milligrams per week, split into two injections weekly for "stable blood levels." They also claim cypionate is "the most common type of testosterone that is prescribed for TRT." The video wraps with a referral pitch for an online TRT clinic, directing viewers to comment for more information.

That's the full claim set: a specific dose, an injection frequency rationale, and a prevalence claim about cypionate. All three are worth examining separately, because they land differently under scrutiny.

Does the science back this up?

Mostly, yes, with one significant asterisk around the dose framing. Twice-weekly injections for cypionate are genuinely supported by pharmacokinetics. Cypionate has a half-life of roughly 7-8 days, and splitting doses reduces the peak-to-trough swing in serum testosterone, which matters for symptom stability and potentially for hematocrit management.

Coviello et al. (2004, Journal of Clinical Endocrinology and Metabolism) established that testosterone cypionate and enanthate are the dominant prescribed forms in the United States, so the "most common" claim holds up in the American clinical context. The Endocrine Society's clinical practice guidelines (Bhasin et al., 2018) list both as first-line injectable options. Splitting doses to stabilize levels is also consistent with current prescribing patterns at regulated TRT clinics, making that piece of advice practically sound even if it's not universally mandated.

What did they get wrong (or right)?

The creator gets the mechanism right and the drug right. The twice-weekly split is legitimate clinical reasoning, not bro-science. Credit where it's due.

The problem is the 180mg figure. Presenting a personal dose as informational content, without context, is where this gets slippery. The Endocrine Society guidelines recommend dosing to achieve mid-normal physiological testosterone ranges, typically 400-700 ng/dL trough, not a flat milligram number. Standard starting doses in clinical protocols often range from 100-200mg per week, so 180mg isn't outrageous, but individual response varies substantially based on SHBG levels, injection depth, body composition, and metabolism.

A viewer who hears "180 milligrams" and treats it as a reference point is missing half the picture. No reputable clinician doses by copying someone else's prescription. The video doesn't mention hematocrit monitoring, PSA screening, or fertility implications, all of which the Endocrine Society considers non-negotiable parts of TRT management (Bhasin et al., 2018, Journal of Clinical Endocrinology and Metabolism).

What should you actually know?

Testosterone cypionate is legitimate, widely prescribed, and well-studied. Twice-weekly dosing to reduce fluctuation is a reasonable approach backed by pharmacokinetic data. Those parts are fine.

What this video cannot tell you is what dose is right for you, because that depends on labs, symptoms, baseline hormone levels, and an actual clinical evaluation. A 2020 analysis by Rastrelli et al. in the Journal of Sexual Medicine found that symptom overlap between hypogonadism and other conditions is significant enough that testosterone levels alone are insufficient for diagnosis.

Before starting TRT, you should have total testosterone confirmed low on at least two morning draws, an LH/FSH panel to distinguish primary from secondary hypogonadism, a baseline PSA, and a hematocrit. These aren't bureaucratic hurdles. They're the difference between appropriate therapy and treating the wrong problem entirely.

• Testosterone cypionate is genuinely the most commonly prescribed injectable testosterone in the US
• Twice-weekly injection splits are pharmacokinetically rational for cypionate
• 180mg weekly is within a plausible clinical range but is not a universal starting point
• TRT without baseline labs and ongoing monitoring carries real cardiovascular and fertility risks